GA Taps Former NM, AR Exchange Director Cheryl Gardner As CEO

Georgia continues to make strides in its plan to establish a state-based marketplace, announcing last week that it has tapped health policy and exchange expert Cheryl Gardner to serve as the first CEO of Georgia Access. If approved, Georgia would be the first GOP-led state to switch to a state-run exchange. “Our office has worked tirelessly over the past several years to move Georgia away from reliance on the federal government to provide healthcare to our citizens,” Georgia Insurance Commissioner...
Article Type: 
Tags: 
Site Name: 
InsideHealthPolicy.com
HEA Issue: 
Health Exchange Alert Weekly Report - 06/07/2023
HEA Volume: 
Vol. 11, No. 23
Author: 


Groups Object After CMS Sticks With Registry Plan For Alzheimer’s Drug Coverage

The Alzheimer’s Association is calling participation in registries an “unnecessary barrier” for access to anti-amyloid drugs for Alzheimer’s disease after CMS announced it will immediately cover anti-amyloid drugs for early stages of Alzheimer’s if they receive full, traditional approval from FDA, but is holding firm that all patients receiving the drugs participate in a registry detailing the treatment’s effectiveness. In a statement released Thursday (June 1) , CMS Administrator Chiquita Brooks-LaSure says the class of drugs that aim to slow...
Article Type: 
Tags: 
Site Name: 
InsideHealthPolicy.com
Author: 

States Act On Data Privacy, Audio Only In 2023 Legislative Session

Over half of state legislatures have adjourned for the year, and before doing so many carried through with telehealth bills that expand access and protections for patients through health data privacy measures, audio-only telehealth coverage and interstate licensure flexibilities. Meanwhile, state Medicaid programs continue to grapple with use of out-of-state telehealth providers and whether to extend some of the other virtual care policies in place during the pandemic now that the COVID-19 public health emergency has ended. The state action...
Overline: 
As feds continue to craft permanent telehealth legislation . . .
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 
Topics: 

Expert: Cost Plus’ Injectables Endeavor Will Face Tough Generics Market

Mark Cuban’s online generic drug pharmacy could soon manufacture injectable drugs currently in shortage, but the company will likely run into the same market issues that are, in part, fueling the recent drug shortage spike in the United States, one expert told Inside Health Policy . FDA currently lists more than 130 ongoing shortages in its drug shortage database, ranging from common antibiotics to critical cancer medications. The agency and lawmakers say low generic drug prices are contributing to the...
Article Type: 
Site Name: 
InsideHealthPolicy.com
IDP Issue: 
Inside Drug Pricing - 06/05/2023
IDP Volume: 
Vol. 6, No. 23
Author: 

Cost Plus Enters Biologics Arena With Low-Cost Humira Biosimilar

Coherus BioSciences in July will launch its Humira biosimilar, Yusimry, which will be available through Mark Cuban’s online generic pharmacy Cost Plus Drug Company at a price of $579 plus shipping, marking the first biologic offered by Cost Plus, the companies announced Thursday (June 1) . Two weeks before the announcement, Cuban also indicated Cost Plus , which offers generics at a lower price, will begin manufacturing injectable drugs that are in shortage. Humira, an injectable that’s approved to treat...
Article Type: 
Site Name: 
InsideHealthPolicy.com
IDP Issue: 
Inside Drug Pricing - 06/05/2023
IDP Volume: 
Vol. 6, No. 23
Author: 

Expert: Cost Plus’ Injectables Endeavor Will Face Tough Generics Market

Mark Cuban’s online generic drug pharmacy could soon manufacture injectable drugs currently in shortage, but the company will likely run into the same market issues that are, in part, fueling the recent drug shortage spike in the United States, one expert told Inside Health Policy . FDA currently lists more than 130 ongoing shortages in its drug shortage database, ranging from common antibiotics to critical cancer medications. The agency and lawmakers say low generic drug prices are contributing to the...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 

Cost Plus Enters Biologics Arena With Low-Cost Humira Biosimilar

Coherus BioSciences in July will launch its Humira biosimilar, Yusimry, which will be available through Mark Cuban’s online generic pharmacy Cost Plus Drug Company at a price of $579 plus shipping, marking the first biologic offered by Cost Plus, the companies announced Thursday (June 1) . Two weeks before the announcement, Cuban also indicated Cost Plus , which offers generics at a lower price, will begin manufacturing injectable drugs that are in shortage. Humira, an injectable that’s approved to treat...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 




Pages

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.